Sprint Bioscience AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 39.57 million compared to SEK 0.005 million a year ago. Revenue was SEK 41.18 million compared to SEK 0.02 million a year ago. Net income was SEK 28.62 million compared to net loss of SEK 13.26 million a year ago. Basic earnings per share from continuing operations was SEK 0.41 compared to basic loss per share from continuing operations of SEK 0.33 a year ago.
For the nine months, sales was SEK 39.61 million compared to SEK 0.068 million a year ago. Revenue was SEK 42.79 million compared to SEK 0.098 million a year ago. Net income was SEK 4.61 million compared to net loss of SEK 45.37 million a year ago. Basic earnings per share from continuing operations was SEK 0.07 compared to basic loss per share from continuing operations of SEK 1.14 a year ago.